Elkedonia
3 known investors
Find your way into Elkedonia
214 people in our graph share verified history with the Elkedonia team — schools, employers, funds. One of them is your warm intro.
Laurie Menoudunlockedknows Jocelyne Caboche · together at Centre National pour la Recherche Scientifique (CNRS) (overlapped)
×3knows the team · via Centre National pour la Recherche Scientifique (CNRS)
×5knows the team · via INSEAD
knows the team · via EPFL
×2knows the team · via Pierre and Marie Curie University
Elkedonia is a biotech company developing a novel antidepressant treatment that targets intracellular neuroplasticity pathways rather than synaptic mechanisms, with the goal of providing rapid, long-lasting relief for depression patients. The company aims to create an accessible therapy for all patients regardless of geography, age, or comorbidities, while avoiding dependence, sedation, or psychotic side effects.
Founders & leadership
DC
Delphine CharvininFounding Chief Executive Officer & Board DirectorShe previously served as Chief Scientific Officer at Prexton Therapeutics (acquired by Lundbeck for $1.1 billion), Chief Scientific Officer at Lundbeck, and Chief Scientific Officer and Chief Innovation Officer at Stalicla, and holds 15 years of experience in drug discovery, clinical development, and biotech company building.
MR
Mélanie RouillierinVP, Chief Operations Officer & Co-FounderMélanie Rouillier is a PMP-certified drug discovery project manager with 17 years of experience in small-molecule drug discovery from library screening through the pre-clinical phase, including 11 years of scientific project management across public-private partnership and startup-studio settings and expertise in in vitro assay development and identifying allosteric modulators targeting GPCRs in central nervous system diseases. She is VP, Chief Operating Officer, and co-founder of Elkedonia, a biotech company developing an antidepressant that targets intracellular neuroplasticity pathways.
JC
Jocelyne CabocheinPresident of the Scientific Advisory Board & Co-FounderJocelyne Caboche is a research director at the CNRS and neurobiologist with expertise in psychiatric disease, including addiction, depression, and anxiety disorders. She co-founded Elkedonia to translate neuroscience research into therapeutic strategies for mood and psychiatric conditions.
Investors · 3
Funding
SEC filings, press & company announcements- Undisclosed amountSeed RoundJul 2025Source ↗
- Undisclosed amountSeed RoundJun 2025 · 3 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Elkedonia do?
- Elkedonia is a biotech company developing a novel antidepressant treatment that targets intracellular neuroplasticity pathways rather than synaptic mechanisms, with the goal of providing rapid, long-lasting relief for depression patients. The company aims to create an accessible therapy for all patients regardless of geography, age, or comorbidities, while avoiding dependence, sedation, or psychotic side effects.
- Who founded Elkedonia?
- Elkedonia was founded by Delphine Charvin, Mélanie Rouillier, Jocelyne Caboche.
- Who are Elkedonia's investors?
- Elkedonia's investors include Angelini Ventures, CARMA FUND, Kurma Partners.